glp-1 weight loss before and after Body Image Distortion Common With Drugs: Experts The Slim Down - News
Description
Several DPP-4 inhibitors with distinct structures have been approved for clinical use, including sitagliptin, alogliptin, linagliptin, gemigliptin, anagliptin, and teneligliptin (22) (Appendix 1 in Supplementary File)
While some patients report increased skin dryness or sensitivity to touch, temperature, or topical products during treatment, these symptoms are not definitively linked to semaglutide and may have other causes that should be evaluated by a healthcare provider
Women of childbearing age
From weight loss to neurological deficits: a case of Wernickes encephalopathy stemming from prescription weight loss medication
Nevertheless, careful patient selection and ongoing monitoring are essential to mitigate potential risks
